These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 6419319)
21. Protective activity of immune sera against extracellular slime from Pseudomonas aeruginosa on experimental infection in mice. Sokalska M; Maresz-Babczyszyn J Arch Immunol Ther Exp (Warsz); 1981; 29(5):643-52. PubMed ID: 6812542 [TBL] [Abstract][Full Text] [Related]
22. Comparative evaluation of mitogenicity and basement-membrane-degrading activity of Pseudomonas aeruginosa slime glycolipoprotein and alginate. Anastassiou ED; Karakiulakis G; Missirlis E; Maragoudakis ME; Dimitracopoulos G J Clin Microbiol; 1989 Mar; 27(3):490-4. PubMed ID: 2497138 [TBL] [Abstract][Full Text] [Related]
23. Phagocytosis and intracellular killing of mucoid and nonmucoid variants of Pseudomonas aeruginosa by polymorphonuclear leukocytes: effect of specific immune sera. Gościniak G; Maresz-Babczyszyn J; Grzybek-Hryncewicz K Arch Immunol Ther Exp (Warsz); 1984; 32(4):467-79. PubMed ID: 6442852 [TBL] [Abstract][Full Text] [Related]
24. Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. III. Polyvalent serum against three mucoid immunotypes potentiates phagocytosis of all (7) mucoid immunotypes. Gościniak G; Grzybek-Hryncewicz K Arch Immunol Ther Exp (Warsz); 1988; 36(2):195-203. PubMed ID: 3149178 [TBL] [Abstract][Full Text] [Related]
25. [Obtaining of outer membrane protein I of Pseudomonas aeruginosa and assessment of its antigenic properties]. Gatypova EV; Zlygostev SA; Kaloshin AA; Mikhaĭlova NA Zh Mikrobiol Epidemiol Immunobiol; 2008; (6):50-3. PubMed ID: 19189463 [TBL] [Abstract][Full Text] [Related]
26. Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. I. Induction of homologous immunity by nonmucoid strains of P. aeruginosa. Gościniak G; Grzybek-Hryncewicz K Arch Immunol Ther Exp (Warsz); 1988; 36(2):177-84. PubMed ID: 2467637 [TBL] [Abstract][Full Text] [Related]
27. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577 [TBL] [Abstract][Full Text] [Related]
29. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. DiGiandomenico A; Rao J; Harcher K; Zaidi TS; Gardner J; Neely AN; Pier GB; Goldberg JB Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4624-9. PubMed ID: 17360574 [TBL] [Abstract][Full Text] [Related]
30. [Pseudomonas aeruginosa slime: chemical composition and biological characteristics]. Moroz AF; Antsiferova NG; Aleksandrov AD Zh Mikrobiol Epidemiol Immunobiol; 1981 Nov; (11):6-12. PubMed ID: 6172917 [No Abstract] [Full Text] [Related]
31. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity. Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907 [TBL] [Abstract][Full Text] [Related]
32. A new scheme for additional typing of P. aeruginosa using antisera prepared against glycopolypeptide derived from the slime of the microorganisms. Nadaud M Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Aug; 260(1):71-80. PubMed ID: 2414949 [TBL] [Abstract][Full Text] [Related]
33. Phagocytosis and intracellular killing of Pseudomonas aeruginosa by peritoneal macrophages of mice. Maresz-Babczyszyn J; Czarny A; Lagowska-Złotorzycka M Arch Immunol Ther Exp (Warsz); 1984; 32(4):481-7. PubMed ID: 6442853 [TBL] [Abstract][Full Text] [Related]
34. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100 [TBL] [Abstract][Full Text] [Related]
35. Studies of lung infections caused by Pseudomonas aeruginosa in mice treated with cyclophosphamide. Mayer P; Walzl H Infection; 1983; 11(2):87-96. PubMed ID: 6408008 [TBL] [Abstract][Full Text] [Related]
37. Investigation on extracellular slime from Pseudomonas aeruginosa as interferon inducer in mice. Cembrzyńska-Nowak M; Czarny A Arch Immunol Ther Exp (Warsz); 1988; 36(2):167-76. PubMed ID: 2467636 [TBL] [Abstract][Full Text] [Related]
38. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. Young LS; Armstrong D J Infect Dis; 1972 Sep; 126(3):257-76. PubMed ID: 4626509 [No Abstract] [Full Text] [Related]